ANKRD62

Across TCGA pan-cancer cohorts, ANKRD62 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ANKRD62 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ANKRD62 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ANKRD62 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD and LSCC are the cancer types where ANKRD62 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	1.000	0.335	.024	4	view →
LSCC	OS	Quartile	All	0.661	0.927	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ANKRD62–LUAD (OS)

Open the LUAD breakdown →